常规评估患者指数数据3在银屑病关节炎患者中的价值:来自严密控制临床试验和观察性队列的结果
对TICOPA临床试验和LOPAS II观察性队列两个独立数据集进行事后分析,评估RAPID3在银屑病关节炎中的表现。RAPID3与PASDAS在TICOPA中相关系数r=0.79(P<0.01),与DAPSA在LOPAS II中相关系数ρ=0.59(P<0.01),在TICOPA第48周可区分严密控制组与标准治疗组(P<0.01)。RAPID3缓解在MDA与VLDA标准之间区分治疗组。
要点
- RAPID3与PASDAS(TICOPA,r=0.79)和DAPSA(LOPAS II,ρ=0.59)均显著相关(P<0.01)。
- TICOPA第48周RAPID3区分严密控制与标准治疗的能力与DAPSA和PASDAS相当(P<0.01)。
- RAPID3缓解区分TICOPA治疗组的能力介于MDA和VLDA标准之间。
核心结论
- RAPID3在银屑病关节炎中提供的信息与PASDAS和DAPSA相当,且在日常临床诊疗中可行性更高。
研究设计与样本
- 对TICOPA临床试验和LOPAS II观察性队列两个独立数据集进行事后分析。
- RAPID3范围为0-30分,为健康评估问卷残疾指数(由0-3重新计算)、疼痛视觉模拟量表(VAS)和总体VAS三个0-10分评分的总和。
主要发现
- RAPID3与PASDAS在TICOPA中显著相关(r=0.79,P<0.01),与DAPSA在LOPAS II中显著相关(ρ=0.59,P<0.01),并与两个数据集中大多数其他指标显著相关。
- RAPID3在TICOPA第48周区分严密控制与标准治疗的水平与DAPSA和PASDAS相当(P<0.01)。
- RAPID3缓解区分TICOPA治疗组的能力介于MDA和VLDA标准之间。
关键数值与推荐
- RAPID3与PASDAS在TICOPA中相关系数r=0.79(P<0.01)。
- RAPID3与DAPSA在LOPAS II中相关系数ρ=0.59(P<0.01)。
- RAPID3在TICOPA第48周区分严密控制与标准治疗(P<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the Routine Assessment of Patient Index Data 3 (RAPID3), a patient-reported, composite index, designed initially for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed RAPID3 in patients with psoriatic arthritis (PsA). METHODS: Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis (TICOPA) clinical trial, and the Long-Term Outcome in Psoriatic Arthritis Study (LOPAS II), an observational cohort. RAPID3 (range 0-30) is the total of three 0-10 scores for the Health Assessment Questionnaire disability index (recalculated from 0-3), pain visual analog scale (VAS), and global VAS. RAPID3 scores were compared to the Psoriatic Arthritis Disease Activity Score (PASDAS), the Disease Activity in Psoriatic Arthritis (DAPSA), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, SEM, smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA). RESULTS: RAPID3 was correlated significantly with PASDAS in TICOPA (r = 0.79, P < 0.01) and with DAPSA in LOPAS II (ρ = 0.59, P < 0.01), and with most other measures in both data sets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS (P < 0.01). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria. CONCLUSION: RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.
引用
- Coates LC, Tillett W, Shaddick G, et al. Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. Arthritis Care Res (Hoboken). 2018. PMID: 29112801. doi:10.1002/acr.23460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。